首页 | 本学科首页   官方微博 | 高级检索  
     

曲美他嗪联合替米沙坦、比索洛尔治疗酒精性心肌病疗效观察
引用本文:杨建梅. 曲美他嗪联合替米沙坦、比索洛尔治疗酒精性心肌病疗效观察[J]. 心血管病防治知识, 2014, 0(10): 39-41
作者姓名:杨建梅
作者单位:云南省临沧市双江县人民医院;
摘    要:目的观察曲美他嗪联合替米沙坦、比索洛尔治疗酒精性心肌病的临床疗效。方法选取我院收治的酒精性心肌病患者64例,将其随机分为对照组和观察组。对照组采用替米沙坦、比索洛尔等常规治疗;观察组在对照组的基础上加用曲美他嗪治疗。分别测量两组治疗前后的血浆脑钠肽(BNP)水平和彩色超声心动图各项指标变化情况。结果治疗3个月后,两组彩色超声心动图各项指标比较差异无统计学意义(P〉0.05);治疗6个月后,观察组彩色心动图各项指标参数明显优于对照组,组间比较差异有统计学意义(P〈0.05);治疗前,两组血浆脑钠肽水平比较差异无统计学意义(P〉0.05);治疗后,两组患者血浆脑钠肽水平均有所下降,但观察组下降幅度明显优于对照组,尤其是治疗6个月后更加显著,组间比较差异有统计学意义(P〈0.05)。结论对于酒精性心肌病患者,采用曲美他嗪联合替米沙坦、比索洛尔治疗的疗效确切,可有效改善患者左心室收缩功能,降低血浆脑钠肽水平,值得临床推广及应用。

关 键 词:酒精性心肌病  曲美他嗪  替米沙坦  比索洛尔  临床疗效

Clinical efficacy of trimetazidine combined with telmisartan and bisoprolol in treatment of alcoholic cardiomyopathy
YANG Jian-mei. Clinical efficacy of trimetazidine combined with telmisartan and bisoprolol in treatment of alcoholic cardiomyopathy[J]. , 2014, 0(10): 39-41
Authors:YANG Jian-mei
Affiliation:YANG Jian-mei;Shuangjiang County People's Hospital;
Abstract:Objective To evaluate the clinical efficacy of trimetazidine combined with telmisartan and bisoprolol in the treatment of alcoholic cardiomyopathy(ACM). Methods A total of 64 ACM patients admitted to our hospital were randomly allocated to control group and observation group. The control group was routinely treated with telmisartan and bisoprolol, and the observation group was treated with trimetazidine in addition to the routine treatment. The levels of blood brain natriuretic peptide(BNP) and changes in various parameters of color echocardiography before and after treatment in both groups were measured. Results After 3 months of treatment, no significant differences in all the echocardiographic parameters were observed between the two groups(P 0.05). After 6 months of treatment, the echocardiographic parameters in the observation group were significantly improved compared with those in the control group(P〈0.05). Before the treatment, there was no significant difference in the blood BNP level between the two groups(P 0.05). After the treatment, the blood BNP level decreased in both groups, with a more prominent decrease in the observation group, and the difference was significant after 6 months of treatment(P〈0.05). Conclusion The combination therapy of trimetazidine with telmisartan and bisoprolol shows definite therapeutic effects in ACM patients. It effectively improves the left ventricular systolic function and reduces the blood BNP level. Its clinical application is highly recommended.
Keywords:Alcoholic cardiomyopathy  Trimetazidine  Telmisartan  Bisoprolol  Clinical efficacy
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号